BR112016019893B1 - Composição - Google Patents

Composição Download PDF

Info

Publication number
BR112016019893B1
BR112016019893B1 BR112016019893-0A BR112016019893A BR112016019893B1 BR 112016019893 B1 BR112016019893 B1 BR 112016019893B1 BR 112016019893 A BR112016019893 A BR 112016019893A BR 112016019893 B1 BR112016019893 B1 BR 112016019893B1
Authority
BR
Brazil
Prior art keywords
mol
rhgus
glucuronidase
recombinant
recombinant glycoprotein
Prior art date
Application number
BR112016019893-0A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016019893A2 (pt
Inventor
Steven Jungles
Gabrielle Morris
Jeff Grubb
Michael Vellard
Emil D. Kakkis
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of BR112016019893A2 publication Critical patent/BR112016019893A2/pt
Publication of BR112016019893B1 publication Critical patent/BR112016019893B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112016019893-0A 2014-03-05 2015-03-05 Composição BR112016019893B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461948421P 2014-03-05 2014-03-05
US61/948,421 2014-03-05
US201562114313P 2015-02-10 2015-02-10
US62/114,313 2015-02-10
PCT/US2015/018859 WO2015134696A1 (en) 2014-03-05 2015-03-05 Sialylated glycoprotein compositions and uses thereof

Publications (2)

Publication Number Publication Date
BR112016019893A2 BR112016019893A2 (pt) 2017-10-24
BR112016019893B1 true BR112016019893B1 (pt) 2023-02-14

Family

ID=54016314

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016019893-0A BR112016019893B1 (pt) 2014-03-05 2015-03-05 Composição

Country Status (17)

Country Link
US (9) US9457067B2 (enExample)
EP (1) EP3113781B1 (enExample)
JP (1) JP6581590B2 (enExample)
KR (1) KR102150481B1 (enExample)
CN (1) CN106102749B (enExample)
AU (1) AU2015227137B2 (enExample)
BR (1) BR112016019893B1 (enExample)
CA (1) CA2940318C (enExample)
ES (1) ES2704923T3 (enExample)
IL (1) IL247550B (enExample)
MX (1) MX368972B (enExample)
MY (1) MY188028A (enExample)
PE (1) PE20161417A1 (enExample)
PH (1) PH12016501658A1 (enExample)
RU (1) RU2689119C2 (enExample)
TW (1) TWI702049B (enExample)
WO (1) WO2015134696A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016019893B1 (pt) 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição
US12391907B2 (en) 2017-12-13 2025-08-19 Neogen Food Safety Us Holdco Corporation Water-reconstitutable culture medium resistant to liquefaction by microorganisms
TWI667252B (zh) * 2018-07-13 2019-08-01 中原大學 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
ES2285188T3 (es) * 2002-07-15 2007-11-16 Immunex Corporation Metodo y medios para controlar sialilacion de proteinas producidas por celulas de mamifero.
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
EP2428225A3 (en) * 2006-09-10 2012-05-09 Glycotope GmbH Use of human cells of myeloid leukaemia origin for expression of antibodies
WO2008109677A2 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
KR101241322B1 (ko) * 2010-02-08 2013-03-11 한국과학기술원 시알산 함량이 높은 재조합 당단백질의 제조 방법
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101457514B1 (ko) * 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
BR112016019893B1 (pt) 2014-03-05 2023-02-14 Ultragenyx Pharmaceutical Inc Composição

Also Published As

Publication number Publication date
US20190054153A1 (en) 2019-02-21
US20240245759A1 (en) 2024-07-25
EP3113781A4 (en) 2017-08-09
US9457068B2 (en) 2016-10-04
IL247550B (en) 2020-10-29
JP6581590B2 (ja) 2019-09-25
BR112016019893A2 (pt) 2017-10-24
US20160367646A1 (en) 2016-12-22
AU2015227137A1 (en) 2016-09-15
CA2940318C (en) 2020-09-22
US20170326210A1 (en) 2017-11-16
US20200282028A1 (en) 2020-09-10
MX368972B (es) 2019-10-23
US20150250860A1 (en) 2015-09-10
PE20161417A1 (es) 2017-01-22
US9457067B2 (en) 2016-10-04
CN106102749B (zh) 2019-07-12
IL247550A0 (en) 2016-11-30
ES2704923T3 (es) 2019-03-20
MY188028A (en) 2021-11-10
WO2015134696A1 (en) 2015-09-11
PH12016501658A1 (en) 2016-10-03
MX2016011416A (es) 2016-12-02
RU2016138790A3 (enExample) 2018-08-23
US9937243B2 (en) 2018-04-10
AU2015227137B2 (en) 2019-06-06
US20150366951A1 (en) 2015-12-24
EP3113781A1 (en) 2017-01-11
RU2689119C2 (ru) 2019-05-24
CA2940318A1 (en) 2015-09-11
TWI702049B (zh) 2020-08-21
US20220202915A1 (en) 2022-06-30
KR20160127124A (ko) 2016-11-02
US20260077025A1 (en) 2026-03-19
US9687532B2 (en) 2017-06-27
JP2017508455A (ja) 2017-03-30
CN106102749A (zh) 2016-11-09
KR102150481B1 (ko) 2020-09-02
TW201615210A (zh) 2016-05-01
RU2016138790A (ru) 2018-04-09
EP3113781B1 (en) 2018-11-21

Similar Documents

Publication Publication Date Title
US20240245759A1 (en) Sialylated glycoprotein compositions and uses thereof
KR102444612B1 (ko) 재조합 산 알파-글루코시다제를 포함하는 제형
JP2024063015A (ja) 高ｍ６ｐ組換えタンパク質の選択方法
JP5850435B2 (ja) ヒトｆｇｆ１９活性の正確で高感度な測定方法ならびにヒトｆｇｆ１９活性の制御剤
BRPI0309665B1 (pt) Método para analisar uma preparação de alfagalactosidase a
KR20230041833A (ko) 폼페병 치료용의 강화된 산 알파-글루코시다제
US20180185495A1 (en) Therapeutic compositions of alpha-l-iduronidase, iduronate-2-sulfatase, and alpha-galactosidase a and methods of use thereof
ES2883844T3 (es) Alfa-glucosidasa ácida aumentada para el tratamiento de la enfermedad de Pompe
BR122024018518A2 (pt) Método para seleção de proteínas recombinantes ricas em m6p
BR112018070189B1 (pt) Método para seleção de proteínas recombinantes ricas em m6p
NZ786386A (en) Formulations comprising recombinant acid alpha-glucosidase

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/03/2015, OBSERVADAS AS CONDICOES LEGAIS